Clinical trials: Myeloid Diseases
Chronic Myeloid Leukemia
TIGIT in Patients With Chronic Myeloid Leukemia
To expresse TIGIT in NK Cells in Patients with Chronic Myeloid Leukemia
- Trial name
- NCT04818619
- Testing
- flow cytometry test
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Assiut University
Acute Myeloid Leukemia
Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia
Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline…
- Trial name
- NUCLARA (NCT03234985)
- Testing
- Biological analyses
- Where
- France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Brain and Central Nervous System Tumors, Leukemia
Metabolic Syndrome in Childhood Cancer Survivors
RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood cancer may help doctors learn more about the disease.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Metabolic Syndrome
- Trial name
- NCT00920738
- Testing
- metabolic assessment, questionnaire administration
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Acute Myeloid Leukemia, Cachexia
Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia
This cohort study aims to investigate the composition and activity of the gut microbiota of patients newly diagnosed for acute myeloid leukemia (AML), in relationship with their food habits and cachectic hallmarks.
- Trial name
- MicroAML (NCT03881826)
- Testing
- collection of clinical data and biological samples
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Université Catholique de Louvain
Thyroid Cancer
Myeloid Cell Reprogramming in Thyroid Carcinoma
This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells (peripheral blood and bone…
- Trial name
- NCT03397238
- Where
- Netherlands
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Leukemia, Myeloid, Chronic-Phase
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
The main objective of this study is to evaluate the existence of a relationship between the presence of certain abl polymorphisms (or haplotypes) upon CML diagnosis and the occurrence of primary resistance to the treatment of CML…
- Trial name
- abl LMC (NCT01650467)
- Where
- 3 sites in France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
- Trial name
- NCT06566742
- Testing
- Olutasidenib
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
CHIP in Health and Disease
Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic…
- Conditions
- Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndrome
- Trial name
- CHIP2 (NCT07780552)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls
Myelodysplastic syndromes (MDS) is a group of heterogeneous diseases characterised by the clonal evolution of dysplastic hematopoietic stem cells.
- Trial name
- PLASMYC (NCT02809222)
- Testing
- Samples, Quality of life questionnaire
- Where
- 2 sites in France
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
Genetic mutations have closely linked to the pathogenesis and prognostication of myeloid cancers. In addition, a number of molecularly targeted agents have been developed in recent years.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Aplastic Anemia
- Trial name
- NCT04060485
- Where
- Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors
Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects
The purpose of this study is to evaluate safety and tolerance by comparing pharmacokinetic characteristics between the Luckyvec 400mg tablet(x 1T) and Glivec 100mg(x 4T) when administered a single-dose to healthy volunteers.
- Trial name
- Imatinib (NCT01270984)
- Testing
- Luckyvec 400mg film coated tablet, Glivec 100mg film coated tablet
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Obesity
Myeloid to Adipocyte Transdifferentiation in Human Cells
In order to design new programs to help prevent weight gain, promote successful and sustainable weight loss, and help treat diseases related to obesity, the investigators need a better understanding of why accumulating fat in…
- Trial name
- MYTH (NCT02654925)
- Testing
- Adipose Tissue Biopsy
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Periodontitis
Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis
Etiopathology of periodontitis is complex and various risk factors are known : Bacterial factors: major risk factor. Although the presence of periodontopathogen bacteria is necessary for the onset of periodontitis, these…
- Trial name
- TREM (NCT02873949)
- Testing
- Crevicular samples (1-10µl), Saliva samples (1ml), Etiologic treatment
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Acute Myeloid Leukemia (AML)
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients
This leukemia is characterized by a poor prognosis for most patients, as they have a high relapse rate despite aggressive treatment with chemotherapy agents and allogeneic bone marrow transplantation.
- Trial name
- NCT03204838
- Testing
- IDH mutation test performed at diagnosis
- Where
- Mexico
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospital General de Mexico
Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant in treating patients with leukemia or…
- Conditions
- Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma
- Trial name
- NCT02424968
- Testing
- Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Robert Lowsky
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Myeloid Chimerism
Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
Background: Sickle cell disease can often be treated with blood stem cell transplants. But for some people the disease returns. This study will give a second transplant to people whose disease has returned but still have some…
- Trial name
- NCT04008368
- Testing
- CliniMACS CD34 Reagent
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloid Leukemia
TGRX-678 Pharmacokinetic Mass Balance
This is a pharmacokinetic study for [14C]TGRX-678 on mass balance to evaluate distribution, metabolism and excretion of TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia.
- Trial name
- NCT06986772
- Testing
- [14C]TGRX-678
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.